It's been approved for people with type 1 diabetes over the age of 14. It works by automatically monitoring a person’s blood sugar levels and administering insulin as needed - no constant checking and injecting required.
The pump is about the size of a deck of cards and can be worn on a belt or carried in a pocket.
The MiniMed 670G, referred to as a 'hybrid closed loop' system, combines both the glucose monitor and the insulin pump in one device.
According to the FDA, the device measures blood sugar every five minutes, then responds by sending insulin into the body, or holding steady. Diabetics can also manually request insulin around mealtimes.
A clinical trial of the MiniMed 670G involving 123 people with type 1 diabetes had no serious adverse events, though the FDA notes that "risks may include hypoglycemia, hyperglycemia, as well as skin irritation or redness around the device’s infusion patch."